CARS1 and cancer: The results described above demonstrate that it is possible to combine the advantages of TCRs and CARs, creating T cells with high-affinity, antibody-derived receptors (from the CAR component) that can specifically react with cancer cells bearing extremely low antigen densities (from the TCR component).